Anebulo Pharmaceuticals Inc(ANEB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:00 PM ET (Korea 10/24 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.19 | Insider Own | 40.54% | Shs Outstand | 41.1M | Perf Week | -16.49% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 24.3M | Perf Month | -62.11% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 54.45% | Short Float | 0.6% | Perf Quarter | -84.87% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -0.4% | Short Ratio | 1.47 | Perf Half Y | -85.37% |
| Sales | 0.00B | P/B | 1.86 | EPS next 5Y | - | ROA | -63.16% | Short Interest | 0.15M | Perf YTD | -64.36% |
| Book/sh | 0.19 | P/C | 1.62 | EPS past 3/5Y | 4.97% -102.33% | ROE | -69.69% | 52W High | -89.47% ($3.42) | Perf Year | -70% |
| Cash/sh | 0.22 | P/FCF | - | Sales past 3/5Y | - | ROIC | -100.53% | 52W Low | 2.8% ($0.35) | Perf 3Y | -87.59% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 33.15% | Gross Margin | - | Volatility(W/M) | 20.46% 13.97% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.24 | EPS Q/Q | 45.77% | Profit Margin | - | RSI (14) | 17.88 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.24 | Sales Q/Q | - | SMA20 | -38.08% ($0.58) | Beta | -0.7 | Target Price | $3 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/2/12 | SMA50 | -63.51% ($0.99) | Rel Volume | 0 | Prev Close | $0.36 |
| Employees | 3 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -80.48% ($1.84) | Avg Volume(3M) | 0.10M | Price | $0.36 |
| IPO | 2021/5/7 | Option/Short | No/Yes | Trades | 0 | Volume | - | Change | - |
🔬 Anebulo Pharmaceuticals (ANEB) is a biotechnology company specializing in the development of novel antidotes and antagonists designed to rapidly alleviate symptoms of acute cannabis intoxication and central nervous system-related metabolic disorders.
Over the past 1 year, on the lower side
89% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
ANEB has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -87.6%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 54.5%.
Tap to view numbers
It ranks #476 of 596 in the industry
Based on market cap of $15M.
ANEB#476 Anebulo Pharmaceuticals Inc $15M PER - 
AKTX#476 Akari Therapeutics Plc ADR $14M PER - 
GUTS#477 Fractyl Health Inc $14M PER - 
NCEL#478 NewcelX Ltd $14M PER - 
BCDA#479 BioCardia Inc $14M PER - 
FAQ
What kind of company is ANEB?
ANEB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ANEB?
The market cap of ANEB is approximately $15M, ranking 5,361 within its sector.
What is the 52-week high and low for ANEB?
ANEB has recorded a 52-week high of $3.42 and a low of $0.35.
